tech_banner
PhosphoSolutions/p62 (Ser28) Antibody/p196-28/100 µl

Rabbit polyclonal antibody

Pooled Serum
Size:
100 µl
Formulation:
Affinity Purified from Pooled Serum
Specificity:
Human, Non-human primate
Applications:
WB 1:500
Species:
Rabbit
Molecular Reference:
~48 kDa
Cite This Antibody:
PhosphoSolutions Cat# p196-28, RRID:AB_2492197
Antigen/Purification: ExpandCollapse

The antigen is a phosphopeptide corresponding to amino acid residues surrounding the phospho-Ser28 of p62.

The antibody is prepared from pooled rabbit serum by affinity purification via sequential chromatography on phospho- and dephospho- peptide affinity columns.

Biological Significance: ExpandCollapse

p62, also known as sequestosome1 (SQSTM1), is a shuttle protein transporting polyubiquitinated proteins for both proteasomal and lysosomal degradation. p62 is an integral component of inclusions in brains of various neurodegenerative disorders, including Alzheimer disease (AD) neurofibrillary tangles (NFTs) and Lewy bodies in Parkinson disease (Nogalaska et al., 2009). p62 plays an important role in the protection of cells from the toxicity of misfolded proteins by enhancing aggregate formation especially in the later stages (Nakaso et al., 2004). Phosphorylation of Ser28 has recently been demonstrated to be related to the pathogenesis of Parkinson’s disease.

Storage

100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg BSA per ml and 50% glycerol. Adequate amount of material to conduct 10-mini Western Blots.

For long term storage –20° C is recommended. Stable at –20° C for at least 1 year.

General References

Nogalska A, Terracciano C, D’Agostino C, Engel WK, Askanas V (2009). p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol. 3:407-13.

Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, Araga S, Yanagawa T, Ishii T, Nakashima K. (2004). Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson’s disease. Brain Res. 1-2: 42-51.